Hims & Hers' (NYSE: HIMS) August price dip is an opportunity to buy, but investors shouldn’t rush to get into this healthcare stock. Forces in play, including high short interest and tepid analyst involvement, are capping gains in 2025 and setting this market up for correction.
The question is how deep the correction will get and when the rebound will begin, and the answers are likely to be moderately deep and relatively soon. Regarding the targets for support, this market’s support is trending higher despite the 2025 volatility and is expected to step in and buy this stock in the $45 to $50 range.
